INDICATION: Dilated Cardiomyopathy

RATIONALE:

Cardiac beta-1 adrenergic receptors (β1-AR), when activated, increase heart rate, contractility, and cardiac output. There is a high prevalence of agonistic autoantibodies that activate cardiac β1-AR in multiple cardiomyopathies, which lead to dilation of the heart and heart failure. The presence of β1-AR autoantibodies correlates with a poor prognosis, and removing or neutralizing β1-AR autoantibodies has shown potential therapeutic benefits. BHV-1600 is a bifunctional MoDE designed to selectively degrade pathogenic β1-AR autoantibodies and should augment the limited efficacy of beta-blockers, providing a novel approach to treating multiple cardiomyopathies.